DSpace at RU >

Browsing by Author Dougados, M.

Full Text	Issue Date	Title	Author(s)
	2010	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.	Smolen, J.S.; Landewe, R.; Breedveld, F.C.; Dougados, M.; Emery, P., et al
	2010	Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data.	Dougados, M.; Wells, G.; Schmidely, N.; Bars, M. Le; Riel, P.L.C.M. van, et al
	2010	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.	Gaujoux-Viala, C.; Smolen, J.S.; Landewe, R.; Dougados, M.; Kvien, T.K., et al
	2009	Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.	Wells, G.; Becker, J.C.; Teng, J.; Dougados, M.; Schiff, M., et al
	2009	Achievement of sustained low disease activity state predicts the absence of structural damage progression in patients with rheumatoid arthritis : insights from the Abatacept database	Wells, G.; Dougados, M.; Smidely, N.; Lafosse, C.; Bars, M. Le, et al
	2009	Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data.	Dougados, M.; Schmidely, N.; Bars, M. Le; Lafosse, C.; Schiff, M., et al
	2008	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.	Aletaha, D.; Landewe, R.B.; Karonitsch, T.; Bathon, J.; Boers, M., et al
	2008	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.	Aletaha, D.; Landewe, R.B.; Karonitsch, T.; Bathon, J.; Boers, M., et al
	2008	Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.	Karonitsch, T.; Aletaha, D.; Boers, M.; Bombardieri, S.; Combe, B., et al
	2007	Disease activity measures for rheumatoid arthritis.	Dougados, M.; Aletaha, D.; Riel, P.L.C.M. van
	2005	Minimal disease activity for rheumatoid arthritis: a preliminary definition.	Wells, G.A.; Boers, M.; Shea, B.; Brooks, P.M.; Simon, L.S., et al
	2005	When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?	Dougados, M.; Emery, P.; Lemmel, E.M.; Zerbini, C.A.; Brin, S., et al
	2004	Leflunomide : a manageable safety profile	Riel, P.L.C.M. van; Smolen, J.S.; Emery, P.; Kalden, J.R.; Dougados, M., et al
	2004	The efficacy of leflunomide monotherapy in rheumatoid arthritis : towards the goals of disease modifying antirheumatic drug therapy	Smolen, J.S.; Emery, P.; Kalden, J.R.; Riel, P.L.C.M. van; Dougados, M., et al
	2004	Lefunomide in combination therapy	Kalden, J.R.; Smolen, J.S.; Emery, P.; Riel, P.L.C.M. van; Dougados, M., et al